Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 2, 2021

Primary Completion Date

October 22, 2021

Study Completion Date

October 22, 2021

Conditions
Advanced CancerMetastatic Cervical Cancer
Interventions
DRUG

Balstilimab (BAL)

Anti-PD-1 Monoclonal antibody

DRUG

Topotecan

Chemotherapy

DRUG

Vinorelbine

Chemotherapy

DRUG

Gemcitabine

Chemotherapy

DRUG

Irinotecan

Chemotherapy

DRUG

Pemetrexed

Chemotherapy

Trial Locations (3)

87109

Optimum Research (Southwest Women's Oncology Center), Albuquerque

0014

Hematology Center after prof. R. Yeolyan, Yerevan

0052

National Center of Oncology named after V.A. Fanarjian, Yerevan

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

European Network of Gynaecological Oncological Trial Groups (ENGOT)

OTHER

lead

Agenus Inc.

INDUSTRY